Actinogen Medical Limited (ACW:ASX)


right-arrow Created with Sketch. -0.003 (-5.26%)
MCAP $89.67M
Last trade 16.10pm 10/05/2021 20mins delayed

Latest Announcements

10/05/2021ACWActinogen Medical Limited
30/04/2021ACWActinogen Medical Limited
21/04/2021 Price SensitivePSACWActinogen Medical Limited
21/04/2021 Price SensitivePSACWActinogen Medical Limited
29/03/2021ACWActinogen Medical Limited
24/03/2021ACWActinogen Medical Limited
24/03/2021 Price SensitivePSACWActinogen Medical Limited
15/03/2021ACWActinogen Medical Limited

Company Overview

Actinogen Medical Limited, formerly Actinogen Limited, is a clinical-stage biotechnology company. The Company focuses on the treatment of Alzheimer's disease and age-related neurodegenerative diseases. The Company is engaged in treating cognitive impairment in chronic neurodegenerative diseases through the inhibition of cortisol production. The Company's Xanamem is a drug under development for the treatment of Alzheimer's disease, which is designed to block the production of cortisol in the brain. Xanamem's mechanism of action is to block the activity of a specific enzyme in the brain, the 11B-HSD1 enzyme. It focuses on Xanamem in the clinical areas, including Diabetes-Cognitive dysfunction, Cognitive dysfunction in Parkinson's Disease, Post Traumatic Stress Disorder (PTSD), Cognitive dysfunction in schizophrenia and depression, and Cardiovascular disease-Post myocardial infarction. It focuses on Phase II XanADu efficacy and safety study with mild Alzheimer's disease patients.

ACW in the news

Search Previous Announcements